Caraco Pharmaceutical (CPD) Receives Favorable Judgment in Patent Case
More News related to CPD
- Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
- Matrix USA Rating Changes 7/3
- Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
- Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
- Caraco Pharmaceutical (CPD) Receives Favorable Judgment in Patent Case
More News related to Corporate News
- Nokia (NOK) and Qualcomm Settle Dispute, Enter License Agreement
- Fannie Mae (FNM) Daniel Hudd Issues Statement About Legislation Passed Today
- NWA (NWA) Cargo Increases Domestic Fuel Surcharges to $0.52/lb
- Solutia (SOA) Boosts Prices Up to 25% on Therminol Heat Transfer Fluids
- Northrop Grumman (NOC) One of Eight Companies to Win $10.12 Billion Military Contract
Caraco Pharmaceutical Laboratories, Ltd. (Amex: CPD) has confirmed that the United States District Court of New Jersey has granted Caraco's motion for summary judgment that the claims of U.S. Patent No. 39,221 that Ortho-McNeil Pharmaceutical, Inc. asserted against Caraco are invalid. Caraco's Tramadol with Acetaminophen product is a generic version of Ortho-McNeil's Ultracet®. The Company commenced shipment of Tramadol with Acetaminophen following the FDA's approval to manufacture, market and distribute the generic product on December 19, 2005, and it has remained on the market since that time.
Caraco Pharmaceutical Laboratories, Ltd. (Caraco) is engaged in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to the wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers throughout the United States and Puerto Rico. [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
